Contineum Therapeutics, Inc. Amortization of Debt Issuance Costs and Discounts
Contineum Therapeutics, Inc. (CTNM) reported Amortization of Debt Issuance Costs and Discounts of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2025-03-06
- Contineum Therapeutics, Inc. amortization of debt issuance costs and discounts for the quarter ending 2024-12-31 was $0.00.
- Contineum Therapeutics, Inc. amortization of debt issuance costs and discounts for the quarter ending 2024-09-30 was $0.00.
- Contineum Therapeutics, Inc. amortization of debt issuance costs and discounts for the quarter ending 2024-06-30 was $0.00.
- Contineum Therapeutics, Inc. amortization of debt issuance costs and discounts for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Contineum Therapeutics, Inc. amortization of debt issuance costs and discounts for fiscal 2024 was $0.00.
- Contineum Therapeutics, Inc. amortization of debt issuance costs and discounts for fiscal 2023 was -$198.00K.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $0.00 derived: sum of 2 quarters · filed 2025-03-06 | $0.00 derived: sum of 3 quarters · filed 2025-03-06 | $0.00 10-K · filed 2025-03-06 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | -$1.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | -$1.00K derived: sum of 3 quarters · filed 2025-03-06 | -$1.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-16 | -$1.00K derived: sum of 2 quarters · filed 2025-03-06 | -$1.00K derived: sum of 3 quarters · filed 2025-03-06 | -$224.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$1.00K derived: sum of 2 quarters · filed 2025-03-06 | -$224.00K derived: sum of 3 quarters · filed 2025-03-06 | -$198.00K 10-K · filed 2025-03-06 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$223.00K derived: sum of 2 quarters · filed 2024-11-06 | -$197.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$223.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$197.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $26.00K 10-Q · filed 2024-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |